Skip to main content

Table 1 Baseline participant characteristics of the intention-to-treat population (n = 206)

From: Clinical and cost effectiveness of arthritis gloves in rheumatoid arthritis (A-GLOVES): randomised controlled trial with economic analysis

  Control (n = 103) Intervention (n = 103)
Age (years): median (IQR) 60 (51,68) 58 (51,67)
Sex: female (%) 82 (80%) 84 (82%)
Diagnosis:
 RA 89 (86%) 87 (84%)
 UIA 14 (14%) 16 (16%)
Hand dominance:
 Right (%) 92 (89%) 93 (90%)
 Left (%) 9 (9%) 3 (3%)
 Both (%) 2 (2%) 7 (7%)
Living status: Alone (%) 18 (17%) 19 (18%)
Living with children: yes (%) 10 (10%) 14 (14%)
Employment status:
 Retired 50 (49%) 44 (43%)
  Due to ill health 9 (9%) 18 (17%)
  Other 41 (40%) 26 (25%)
 Full-time work 24 (24%) 21 (20%)
 Part-time work 13 (13%) 18 (17%)
 Homemaker 9 (9%) 6 (6%)
 Long-term sick 2 (2%) 7 (7%)
 Unemployed 3 (3%) 3 (3%)
 Self-employed 1 (1%) 3 (3%)
 Student 0 (0%) 1 (1%)
 Missing 1. (1%)  
Symptom duration (months):
 Median (IQR) 60 (24,168) 72 (18,174)
Diagnosis duration (months):
 Median (IQR) 48 (10,144) 51 (8,168)
Medication regimen:
 0 DMARDs a 10 11
 1 DMARD 51 56
 2 or more DMARDs 42 36
 Biologics b 15 18
Started new/ changed DMARD or biologic in previous 3 months c: yes (%) 34 (33%) 34 (33%)
  1. aDMARD Disease Modifying Anti-Rheumatic Drug; bparticipants were also prescribed a DMARD; cstratification variable